Lassen Therapeutics: Funding, Investors & Team (Oct 2026)
Lassen Therapeutics specializes in developing antibodies for potential treatments in fibrosis, rare diseases, and oncology. Their leading candidate, LASN01, is a monoclonal antibody designed to target IL-11 receptor alpha (IL-11R). IL-11, a cytokine belonging to the IL-6 family, plays a crucial role in fibrosis and is a significant factor in tumor microenvironment organization and tumor growth. In comparison to targeting other factors such as TGF-β and CTGF, blocking the activity of IL-11 shows promising potential for enhanced effectiveness. The IL-11 protein acts as a mediator between cancer cells and stromal cells, making it a pivotal component in the interaction between the two.
Lassen Therapeutics has raised $85.0M across 1 funding round on record, the most recent a Series B of $85.0M announced in Dec 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lassen Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Lassen Therapeutics Funding Rounds
Lassen Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Lassen Therapeutics Funding Compared to Other Biotechnology Startups
Lassen Therapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lassen Therapeutics in Biotechnology and San Diego
Companies Similar to Lassen Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Lassen Therapeutics Funding FAQs
What does Lassen Therapeutics do?
Lassen Therapeutics specializes in developing antibodies for potential treatments in fibrosis, rare diseases, and oncology. Their leading candidate, LASN01, is a monoclonal antibody designed to target IL-11 receptor alpha (IL-11R). IL-11, a cytokine belonging to the IL-6 family, plays a crucial role in fibrosis and is a significant factor in tumor microenvironment organization and tumor growth. In comparison to targeting other factors such as TGF-β and CTGF, blocking the activity of IL-11 shows promising potential for enhanced effectiveness. The IL-11 protein acts as a mediator between cancer cells and stromal cells, making it a pivotal component in the interaction between the two.
How much funding has Lassen Therapeutics raised?
Lassen Therapeutics has raised $85.0M across 1 round on record. The most recent is a Series B of $85.0M announced in Dec 2023.
When did Lassen Therapeutics last raise funding?
Lassen Therapeutics' most recent funding round on record is a Series B of $85.0M, announced in Dec 2023.
Who founded Lassen Therapeutics?
FundedIQ lists David King (Founder) at Lassen Therapeutics.
Where is Lassen Therapeutics headquartered?
Lassen Therapeutics is based in San Diego, California, United States.
How many employees does Lassen Therapeutics have?
Lassen Therapeutics is in the 11-50 employee band.
How does Lassen Therapeutics' funding compare to other Biotechnology startups?
Lassen Therapeutics' latest round of $85.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Lassen Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lassen Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.